TRVI
Price
$14.81Alerts
Change
-$0.10 (-0.67%)
Updated
Nov 11 closing price
Capitalization
2.04B
131 days until earnings call
Intraday BUY SELL Signals
VERA
Price
$30.48Alerts
Change
+$0.45 (+1.50%)
Updated
Nov 11 closing price
Capitalization
2.15B
133 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

TRVI vs VERA

TRVI vs VERA Comparison Chart in %
View a ticker or compare two or three
VS
TRVI vs. VERA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TRVI is a Hold and VERA is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for TRVI with price predictions
Nov 11, 2026

TRVI's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for TRVI turned positive on October 20, 2026. Looking at past instances where TRVI's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TRVI's RSI Indicator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TRVI as a result. In 70 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

TRVI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +19.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in 240 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 50-day moving average for TRVI moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

TRVI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TRVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.350) is normal, around the industry mean (3.498). P/E Ratio (-40.943) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for VERA with price predictions
Nov 11, 2026

VERA in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026

VERA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 30 cases where VERA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VERA's RSI Oscillator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for VERA just turned positive on October 20, 2026. Looking at past instances where VERA's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.

Following a +5.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where VERA advanced for three days, in 238 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 197 of 228 cases where VERA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where VERA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VERA as a result. In 80 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

VERA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VERA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.264) is normal, around the industry mean (3.498). P/E Ratio (-5.074) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. VERA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VERA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
TRVI: Fundamental Ratings
TRVI
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
PROFIT vs RISK RATING
1..100
23
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
47
P/E GROWTH RATING
1..100
27
SEASONALITY SCORE
1..100
3

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
TRVIVERA
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (TRVI: $14.91 vs. VERA: $30.03)
Brand notoriety: TRVI and VERA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: TRVI: 116% vs. VERA: 80%
Market capitalization -- TRVI: $2.04B vs. VERA: $2.15B
TRVI [@Biotechnology] is valued at $2.04B. VERA’s [@Biotechnology] market capitalization is $2.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TRVI’s FA Score shows that 3 FA rating(s) are green while VERA’s FA Score has 1 green FA rating(s).

  • TRVI’s FA Score: 3 green, 2 red.
  • VERA’s FA Score: 1 green, 4 red.
According to our system of comparison, TRVI is a better buy in the long-term than VERA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TRVI’s TA Score shows that 5 TA indicator(s) are bullish while VERA’s TA Score has 5 bullish TA indicator(s).

  • TRVI’s TA Score: 5 bullish, 5 bearish.
  • VERA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VERA is a better buy in the short-term than TRVI.

Price Growth

TRVI (@Biotechnology) experienced а +7.58% price change this week, while VERA (@Biotechnology) price change was -2.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

TRVI is expected to report earnings on Mar 23, 2027.

VERA is expected to report earnings on Mar 25, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with TSHA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then TSHA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-0.64%
TSHA - TRVI
47%
Loosely correlated
+0.12%
SYRE - TRVI
45%
Loosely correlated
+2.24%
STTK - TRVI
44%
Loosely correlated
+4.12%
MGTX - TRVI
44%
Loosely correlated
+0.62%
RLAY - TRVI
43%
Loosely correlated
-1.10%
More

VERA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERA has been loosely correlated with VKTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if VERA jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERA
1D Price
Change %
VERA100%
+1.50%
VKTX - VERA
44%
Loosely correlated
-0.77%
MGTX - VERA
42%
Loosely correlated
+0.62%
SRRK - VERA
42%
Loosely correlated
-2.92%
NAMS - VERA
41%
Loosely correlated
+8.03%
TRVI - VERA
41%
Loosely correlated
-0.64%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IMFL33.740.19
+0.57%
Invesco International Developed Dynamic Multifactor ETF (IMFL)
SCUS25.05N/A
N/A
Schwab Ultra-Short Income ETF (SCUS)
VALG13.49N/A
N/A
Leverage Shares 2X Long VALE Daily ETF (VALG)
UNHG20.03-0.19
-0.94%
Leverage Shares 2X Long UNH Daily ETF (UNHG)
EUM16.87-0.42
-2.40%
ProShares Short MSCI Emerging Markets (EUM)